Lexeo Therapeutics, Inc.
LXEO
$4.85
$0.194.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 14.72M | 17.17M | 18.37M | 23.42M | 16.56M |
| Gross Profit | -14.72M | -17.17M | -18.37M | -23.42M | -16.56M |
| SG&A Expenses | 15.97M | 16.63M | 9.02M | 8.12M | 6.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.69M | 33.81M | 27.38M | 31.54M | 23.55M |
| Operating Income | -30.69M | -33.81M | -27.38M | -31.54M | -23.55M |
| Income Before Tax | -26.10M | -32.66M | -25.92M | -29.49M | -21.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.10M | -32.66M | -25.92M | -29.49M | -21.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.10M | -32.66M | -25.92M | -29.49M | -21.24M |
| EBIT | -30.69M | -33.81M | -27.38M | -31.54M | -23.55M |
| EBITDA | -30.55M | -33.67M | -27.23M | -31.38M | -23.39M |
| EPS Basic | -0.60 | -0.99 | -0.78 | -0.89 | -0.64 |
| Normalized Basic EPS | -0.42 | -0.62 | -0.49 | -0.56 | -0.40 |
| EPS Diluted | -0.60 | -0.99 | -0.78 | -0.89 | -0.64 |
| Normalized Diluted EPS | -0.42 | -0.62 | -0.49 | -0.56 | -0.40 |
| Average Basic Shares Outstanding | 43.57M | 33.11M | 33.08M | 33.06M | 33.00M |
| Average Diluted Shares Outstanding | 43.57M | 33.11M | 33.08M | 33.06M | 33.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |